Prognostic benefit of TILs independent of clinicopathological and molecular factors

Brummel, Koen; Eerkens, Anneke L.; Bruyn, Marco de; Nijman, Hans W.

doi:10.1038/s41416-023-02335-6

Br J Cancer

2023

DOI: 10.1038/s41416-023-02335-6

|View full text |Cite

Prognostic benefit of TILs independent of clinicopathological and molecular factors

Koen Brummel

Anneke L. Eerkens

Marco de Bruyn

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 8 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

β2-microglobulin expression is associated with aggressive histology, activated tumor immune milieu, and outcome in colon carcinoma

Lee,

Pankaj,

Rickelt

et al. 2024

American Journal of Clinical Pathology

View full text Add to dashboard Cite

Objectives We sought to assess the expression of human leukocyte antigen (HLA) proteins and β2-microglobulin (B2M) in tumor cells and the relationship with immune microenvironment and outcome in colorectal cancer (CRC). Methods A total of 953 CRC cases were evaluated by immunohistochemistry for HLA class I, HLA class II, and B2M. The expression level of these biomarkers was correlated with clinicopathologic information, BRAF V600E and mismatch repair (MMR) proteins, and the quantitated expression levels of immune cells (CD8 and CD163) and immune regulatory proteins (FoxP3, programmed cell death 1 ligand 1 [PD-L1], and LAG3). Results We found that B2M-low tumors were statistically correlated with aggressive histologic features, including higher stage, higher grade, extramural venous invasion, perineural invasion, and distant metastasis. Expression of B2M was positively correlated (R2 = 0.3) and significantly associated with MMR-deficient tumors (P < .001); B2M-low tumors were also associated with an “immune cold”’ microenvironment, including a reduced number of immune cells (CD8 and CD163), reduced expression of immune regulatory proteins by immune cells (PD-L1, FoxP3, and LAG3), and reduced tumor cell expression of PD-L1. These B2M-low tumors correlated with lower disease-specific survival (P = .018), a finding that maintained significance only for the proficient MMR cohort (P = .037). Conclusions Our findings suggest that B2M expression may support predictive models for both outcome and checkpoint inhibitor therapy treatment response for colorectal adenocarcinoma.

show abstract

β2-microglobulin expression is associated with aggressive histology, activated tumor immune milieu, and outcome in colon carcinoma

Lee,

Pankaj,

Rickelt

et al. 2024

American Journal of Clinical Pathology

View full text Add to dashboard Cite

show abstract

Immunotherapy for colorectal cancer

Yu,

Kang,

Lei

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Colorectal cancer is the third most common cancer and the second most lethal cancer in the world. The main cause of the disease is due to dietary and behavioral factors. The treatment of this complex disease is mainly based on traditional treatments, including surgery, radiotherapy, and chemotherapy. Due to its high prevalence and high morbidity, more effective treatments with fewer side effects are urgently needed. In recent years, immunotherapy has become a potential therapeutic alternative and one of the fastest-developing treatments. Immunotherapy inhibits tumor growth by activating or enhancing the immune system to recognize and attack cancer cells. This review presents the latest immunotherapies for immune checkpoint inhibitors, cell therapy, tumor-infiltrating lymphocytes, and oncolytic viruses. Some of these have shown promising results in clinical trials and are used in clinical treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prognostic benefit of TILs independent of clinicopathological and molecular factors

Cited by 2 publications

References 8 publications

β2-microglobulin expression is associated with aggressive histology, activated tumor immune milieu, and outcome in colon carcinoma

β2-microglobulin expression is associated with aggressive histology, activated tumor immune milieu, and outcome in colon carcinoma

Immunotherapy for colorectal cancer

Contact Info

Product

Resources

About